Loading
A phase 1/2 trial of Pembrolizumab, Cetuximab, Afatinib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 is a phase 1/2 interventional study registered as NCT03785249 by Mirati Therapeutics Inc., with 731 participants enrolled, started 2019-01-15 and due to reach its primary completion in 2026-06-23. Interventions recorded: MRTX849, Pembrolizumab, Cetuximab, Afatinib. Conditions listed: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease. No results are recorded here; the registry entry is the source.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Adagrasib joins sotorasib as a later-line option for KRAS G12C pancreatic cancer in guidelines; both drugs are the template for the G12D and pan-RAS inhibitors now in pancreatic trials.
This is the paper Europe PMC returns for registry id NCT03785249 with the most citations, so it is the natural first reading for anyone following the Phase 1 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Adagrasib, Cetuximab, Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
Shares Cetuximab, Bristol Myers Squibb, Pembrolizumab, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant colorectal cancer, Cetuximab, Bristol Myers Squibb, Colorectal cancer.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, Cetuximab, Pembrolizumab.
Shares Adagrasib, KRAS G12C-mutant colorectal cancer, Cetuximab, Colorectal cancer.
Shares Adagrasib, Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
Shares KRYSTAL-1: adagrasib in advanced solid tumours harbouring a KRAS G12C mutation, including pancreatic cancer, KRAS mutation subtypes (G12C, G12D, G12V), Adagrasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma.